SLC5A2 and type 2 diabetes mellitus: However, canagliflozin treatment was associated with a significant risk of lower limb amputations in T2DM patients, which is not seen with other SGLT2 inhibitors (Zinman et al., 2015; Birkeland et al., 2017; Fadini and Avigari, 2017; Neal et al., 2017).